1602P - Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Tomomi Fujii
Citation Annals of Oncology (2016) 27 (6): 545-551. 10.1093/annonc/mdw393
Authors T. Fujii1, K. Shimada1, Y. Tatsumi1, N. Tanaka2, K. Fujimoto3, N. Konishi1
  • 1Pathology, Nara Medical University, 634-8521 - Nara/JP
  • 2Urology, Nara Medical University Hospital, 634-8522 - Kashihara/JP
  • 3Urology, Nara Medical University Hospital, Kashihara/JP



Syndecan-1 is an important regulator, and may contribute to various mechanisms in the progression of prostate cancer, such as cell growth, and epithelial-to-mesenchymal transition (EMT), through regulation of microRNAs (miRNAs). We recently found that miR-331-3p is down-regulated by syndecan-1 silencing in PC3 cells, based on an miRNA expression array and quantitative RT-PCR assay. The aim of the present study was to investigate whether syndecan-1-regulated miR-331-3p expression positively affects EMT.


The expression of miR-331-3p, E-cadherin, and vimentin was detected in twenty-three prostate cancer tissues with in situ hybridization and immunohistochemistry. For functional analysis of miR-331-3p and syndecan-1, miR-331-3p precursor or syndecan-1 siRNA was transfected into PC3 cell lines. Cell proliferation and migration were evaluated with MTS assay and wound healing assay, respectively. For bioinformatics prediction, quantitative RT-PCR and luciferase assay were used to identify the target of the miRNA.


In situ hybridization and immunohistochemistry of radical prostatectomy samples revealed miR-331-3p expression in cancer cells with high Gleason patterns, and EMT was demonstrated by decreased E-cadherin and increased vimentin staining. Overexpression of miR-331-3p up-regulated mesenchymal markers such as vimentin, N-cadherin, and Snail, and down-regulated epithelial markers such as E-cadherin and desmoplakin in the prostate cancer cell line PC3. We identified Neuropilin 2 (NRP2) and nucleus accumbens-associated protein 1 (NACC1) as putative target molecules in silico, as they were closely associated with the expression of miR-331-3p and TGF-ß/Smad 4 signals. Syndecan-1 gene silencing decreased the levels of Dicer, which is involved in miRNA maturation.


miR-331-3p can suppress tumor growth and the migration of prostate cancer cells by targeting NRP2 and NACC1, which may provide a potential therapeutic target for prostate cancer treatment. Moreover, syndecan-1-mediated miRNA maturation by Dicer and miR-331-3p-mediated EMT via effects on TGF-ß/Smad 4 signaling are essential for the development of prostate cancer.

Clinical trial identification

Legal entity responsible for the study

Nara Medical University School of Medicine, Nara, Japan


Grant-in-Aid from the Ministry of Educaion, Culture, Sports, Science and Technology, Japan (26462424)


All authors have declared no conflicts of interest.